definiens: ) is a Captisol Patent within the meaning of 2013 License, and relates to formulations that include β -Cyclodextrin ; WHEREAS, und er the 2013 License, Ligand granted certain rights and licenses to Spectrum in the BCD Patents ; WHEREAS, Acrotech Biopharma LLC is Spectrum ’s successor -in - interest in the 2013 License ; WHEREAS, the BCD Patents are presently listed in FDA ’s Orange Book as c overing Acrotech ’s Evomela ® Melphalan Hydrochloride injection product ( ) ; WHEREAS, [ * * * ] ; WHEREAS, [ * * * ] ; WHEREAS, [ * * * ] ; WHEREAS, [ * * * ] ; WHEREAS, [ * * * ] ; - 1 - WHEREAS, the Parties agree to amend the 2013 License under the terms and conditions herein to accommodate [ * * * ] ; NOW, THEREFORE, in consideration of the good and valuable consideration, the exchange, receipt, and sufficiency of which are acknowledged, the Parties agree as follows : 1.Except as expressly set forth herein, the terms and conditions of the 2013 License shall remain in full force and effect